A detailed history of Israel Englander (Millennium Management LLC) transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 758,740 shares of PMVP stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
758,740
Previous 655,461 15.76%
Holding current value
$1.26 Million
Previous $1.11 Million 10.32%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.51 - $2.21 $155,951 - $228,246
103,279 Added 15.76%
758,740 $1.23 Million
Q1 2024

May 15, 2024

BUY
$1.51 - $3.12 $989,746 - $2.05 Million
655,461 New
655,461 $1.11 Million
Q2 2023

Aug 14, 2023

SELL
$3.94 - $6.27 $833,755 - $1.33 Million
-211,613 Reduced 61.85%
130,539 $817,000
Q1 2023

May 15, 2023

BUY
$4.77 - $9.16 $1.28 Million - $2.46 Million
268,615 Added 365.28%
342,152 $1.63 Million
Q4 2022

Feb 14, 2023

SELL
$8.17 - $12.95 $710,455 - $1.13 Million
-86,959 Reduced 54.18%
73,537 $640,000
Q3 2022

Nov 14, 2022

BUY
$11.4 - $17.18 $1.83 Million - $2.76 Million
160,496 New
160,496 $1.91 Million
Q1 2022

May 16, 2022

SELL
$14.86 - $23.55 $1.02 Million - $1.62 Million
-68,845 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$19.99 - $30.24 $1.38 Million - $2.08 Million
68,845 New
68,845 $1.59 Million
Q2 2021

Aug 16, 2021

SELL
$28.01 - $36.01 $211,755 - $272,235
-7,560 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$30.66 - $49.5 $231,789 - $374,220
7,560 New
7,560 $249,000
Q4 2020

Feb 16, 2021

SELL
$31.86 - $61.51 $8.93 Million - $17.2 Million
-280,425 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$35.5 - $38.0 $9.96 Million - $10.7 Million
280,425 New
280,425 $9.96 Million

Others Institutions Holding PMVP

About PMV Pharmaceuticals, Inc.


  • Ticker PMVP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,622,600
  • Market Cap $75.7M
  • Description
  • PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...
More about PMVP
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.